Description
NandroMix 300 is an oily injection solution containing two Nandrolon esters: Nandrolone Phenylpropionate (NPP) and Nandrolone Decanoate (Deca). The typical split is 100mg NPP plus 200mg Deca per ml for a total concentration of 300mg Nandrolon per ml.
Per study reports the mix formulation delivers a mixed pharmacokinetic profile: the NPP portion provides rapid onset (half-life ~4-5 days), the Deca portion carries the long plateau (~6-12 days). This produces faster action onset times than pure Deca and smoother plasma levels than pure NPP.
Pharmacology corresponds to all Nandrolon esters: low androgenic activity, high anabolic action, weak aromatization to estradiol, 5α-reduction to weakly-androgenic DHN. Prolactin-mediated effects and “Deca dick” phenomenon are documented under NandroMix as with single compounds.
In practice NandroMix is injected weekly or biweekly. Steady-state is established after 3-4 weeks. Mid-cycle adjustments are more difficult through the long Deca portion than with pure NPP - clearance takes weeks.
The mix formulation has a practical advantage: fewer injections per week than pure NPP but faster onset than pure Deca.
You can order NandroMix 300 as an oily injection solution in 10-pack at 300mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
NandroMix 300 combines two Nandrolon esters - the risk profile described in the literature corresponds to all Nandrolon compounds, and the long Deca portion makes clearance slow if side effects occur.
Documented in studies and the application literature:
- Progestagenic and prolactinergic action: both esters act progestagenically and raise prolactin levels. Libido decrease and erectile dysfunction are documented, described in recreational reports as the “Deca dick” phenomenon.
- Suppression of endogenous production: Nandrolon strongly suppresses endogenous testosterone production and suppresses the DHT pathways. Testicular atrophy and reduced fertility are documented, a separate test base is mandatory.
- Weak aromatization: Nandrolon converts only weakly to estradiol, yet water retention is documented at higher doses.
- Cardiovascular and liver: the literature describes an unfavorable lipid profile, cardiac effects in chronic use and mild hepatotoxicity.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Anabolic Effects of Nandrolone Decanoate in Patients Receiving Dialysis - JAMA 1999, Johansen et al: RCT on nandrolone and lean-mass gains, applies class-wide to mix formulations.
- Effects of Resistance Exercise Training and Nandrolone Decanoate on Body Composition and Muscle Function among Patients Who Receive Hemodialysis - JASN 2006, Johansen et al: resistance training plus nandrolone with 3.1 kg lean-mass gain.
- Nandrolone decanoate: Pharmacological properties and therapeutic use in osteoporosis - Clinical Rheumatology 1995, Geusens: pharmacology review of nandrolone esters.
- Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use - Circulation 2017, Baggish et al: cohort study on reduced LV function and coronary atherosclerosis in chronic AAS users.
- Impact of Nandrolone Decanoate on Gene Expression in Endocrine Systems Related to the Adverse Effects of Anabolic Androgenic Steroids - Basic Clin Pharmacol Toxicol 2009, Alsiö et al: gene-expression study on HPTA suppression under nandrolone.
